| Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging M Law, RJ Young, JS Babb, N Peccerelli, S Chheang, ML Gruber, ... Radiology 247 (2), 490-498, 2008 | 613 | 2008 |
| The rsna-asnr-miccai brats 2021 benchmark on brain tumor segmentation and radiogenomic classification U Baid, S Ghodasara, S Mohan, M Bilello, E Calabrese, E Colak, ... arXiv preprint arXiv:2107.02314, 2021 | 550 | 2021 |
| Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid AM Miller, RH Shah, EI Pentsova, M Pourmaleki, S Briggs, N Distefano, ... Nature 565 (7741), 654-658, 2019 | 463 | 2019 |
| Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trials A Shukla‐Dave, NA Obuchowski, TL Chenevert, S Jambawalikar, ... Journal of Magnetic Resonance Imaging 49 (7), e101-e121, 2019 | 322 | 2019 |
| Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 39 (1), 30, 2021 | 285 | 2021 |
| Efficacy of MEK inhibition in patients with histiocytic neoplasms EL Diamond, BH Durham, GA Ulaner, E Drill, J Buthorn, M Ki, L Bitner, ... Nature 567 (7749), 521-524, 2019 | 276 | 2019 |
| Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases ZA Kohutek, Y Yamada, TA Chan, CW Brennan, V Tabar, PH Gutin, ... Journal of neuro-oncology 125, 149-156, 2015 | 270 | 2015 |
| Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma IK Mellinghoff, BM Ellingson, M Touat, E Maher, MI De La Fuente, ... Journal of clinical oncology 38 (29), 3398-3406, 2020 | 210 | 2020 |
| Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma RJ Young, A Gupta, AD Shah, JJ Graber, Z Zhang, W Shi, AI Holodny, ... Neurology 76 (22), 1918-1924, 2011 | 208 | 2011 |
| Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma MI de la Fuente, RJ Young, J Rubel, M Rosenblum, J Tisnado, S Briggs, ... Neuro-oncology 18 (2), 283-290, 2015 | 194 | 2015 |
| Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence AJ Prager, N Martinez, K Beal, A Omuro, Z Zhang, RJ Young American Journal of Neuroradiology 36 (5), 877-885, 2015 | 183 | 2015 |
| Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery D Boothe, R Young, Y Yamada, A Prager, T Chan, K Beal Neuro-oncology 15 (9), 1257-1263, 2013 | 182 | 2013 |
| Background, current role, and potential applications of radiogenomics K Pinker, F Shitano, E Sala, RK Do, RJ Young, AG Wibmer, H Hricak, ... Journal of Magnetic Resonance Imaging 47 (3), 604-620, 2018 | 172 | 2018 |
| Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas M Law, R Young, J Babb, E Pollack, G Johnson American Journal of Neuroradiology 28 (4), 761-766, 2007 | 167 | 2007 |
| MRI perfusion in determining pseudoprogression in patients with glioblastoma RJ Young, A Gupta, AD Shah, JJ Graber, TA Chan, Z Zhang, W Shi, ... Clinical imaging 37 (1), 41-49, 2013 | 160 | 2013 |
| Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial IK Mellinghoff, M Penas-Prado, KB Peters, HA Burris III, EA Maher, ... Clinical Cancer Research 27 (16), 4491-4499, 2021 | 150 | 2021 |
| Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma AA Thomas, J Arevalo-Perez, T Kaley, J Lyo, KK Peck, W Shi, Z Zhang, ... Journal of neuro-oncology 125, 183-190, 2015 | 139 | 2015 |
| Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with … M Law, R Young, J Babb, M Rad, T Sasaki, D Zagzag, G Johnson American journal of neuroradiology 27 (9), 1975-1982, 2006 | 133 | 2006 |
| Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab AL Lin, P Jonsson, V Tabar, TJ Yang, J Cuaron, K Beal, M Cohen, ... The Journal of Clinical Endocrinology & Metabolism 103 (10), 3925-3930, 2018 | 128 | 2018 |
| Genomic correlates of disease progression and treatment response in prospectively characterized gliomas P Jonsson, AL Lin, RJ Young, NM DiStefano, DM Hyman, BT Li, ... Clinical Cancer Research 25 (18), 5537-5547, 2019 | 126 | 2019 |
Andrei HolodnyChief of Neuroradiology, Memorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
